Erythropoietin for Management of Anemia Caused by Chemotherapy

Status Completed

Clinical Trial Summary

This is a phase Ⅱ study of erythropoietin for management of anemia caused by chemotherapy in patients with Diffuse Large B-cell Lymphoma. The investigators want to investigate hematopoietic response of darbepoietin alfa and the quality of life assessment of increasement of hemoglobin.

Clinical Trial Description

Darbepoietin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with malignant lymphoma. Darbepoietin will be applied to R-CHOP(Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) chemotherapy every 21days ± 2days with fixed 360㎍. It will be applied to chemotherapy until increment of hemoglobin 12.0g/dL. If the hemoglobin level exceeds 12.0g/dL, administration of darbepoietin will be temporarily stopped.

And, the questionnaire of the quality of life will be conducted at the baseline, after 2th darbepoietin alfa administration, at study completion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02890602
Study type	Interventional
Source	Kosin University Gospel Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	September 1, 2012
Completion date	December 7, 2017

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Recruiting	`NCT05823701` - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients	Phase 2
Completed	`NCT01691898` - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	Phase 1/Phase 2
Recruiting	`NCT03656835` - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma	N/A
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Active, not recruiting	`NCT02060656` - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)	Phase 2
Active, not recruiting	`NCT01653067` - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma	Phase 2
Enrolling by invitation	`NCT00846157` - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients	Phase 3
Completed	`NCT00440583` - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP	Phase 2
Completed	`NCT01851551` - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL	Phase 1/Phase 2
Recruiting	`NCT04981795` - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed	`NCT01186978` - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma	N/A
Completed	`NCT01197560` - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2/Phase 3
Recruiting	`NCT03246906` - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Phase 2
Not yet recruiting	`NCT05990985` - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.	N/A
Completed	`NCT03630159` - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients	Phase 1
Active, not recruiting	`NCT04529772` - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)	Phase 3
Active, not recruiting	`NCT02900651` - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies	Phase 1
Active, not recruiting	`NCT02481310` - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma	Phase 1/Phase 2
Terminated	`NCT03864419` - Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda	Phase 1